SAB Biotherapeutics takes another big step with COVID-19 therapeutic
SAB Biotherapeutics’ therapeutic for COVID-19 could help target variants and is entering a new stage of testing. And that’s far from the company’s only development.
SAB Biotherapeutics’ therapeutic for COVID-19 could help target variants and is entering a new stage of testing. And that’s far from the company’s only development.
The COVID-19 therapeutic developed and being tested by Sioux Falls-based SAB Biotherapeutics has received an additional $57.5 million from the federal government to continue its work.
The treatments given to President Donald Trump for his case of COVID-19 are also being used in Sioux Falls patients.
“SAB is a very different company today than we were at the beginning of the year.” With unprecedented growth and a one-of-a-kind treatment for COVID-19, SAB Biotherapeutics is just getting started.
A first-of-its-kind approach to targeting COVID-19 has happened between two Sioux Falls-based organizations.
Sioux Falls-based SAB Biotherapeutics has started testing in a human patient for its therapeutic specifically developed for the virus that causes COVID-19.
Sioux Falls-based SAB Biotherapeutics has received an additional $35.6 million in government funding, plus $14 million in series B funding that includes a new investor – global health care leader Merck.
Sioux Falls-based SAB Biotherapeutics has confirmed that its treatment in development specifically for the virus that causes COVID-19 has produced antibodies that neutralized the virus in a way that’s four times as potent as using plasma from recovered patients.
The COVID-19 therapeutic being developed by Sioux Falls-based SAB Biotherapeutics has been featured in a CNN report.
Have you been encouraged by the use of plasma to treat COVID-19? Then you need to know what’s being developed in your own backyard.